We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Symphogen Issued Patent Covering Sympress™ Technology

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Symphogen Issued Patent Covering Sympress™ Technology"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Symphogen has announced that the European Patent Office issued European Patent number 1,583,830 titled, "Method for manufacturing recombinant polyclonal proteins".

The patent broadly covers Symphogen's proprietary method of manufacturing recombinant human polyclonal antibodies (pAb) with the Sympress™ manufacturing platform.

In addition to covering Symphogen's proprietary gene technology for polyclonal antibody production, the patent also covers use of pAb manufacturing cell lines and Symphogen's polyclonal antibody expression libraries.

"We are the only company with a viable platform for producing recombinant polyclonal proteins such as antibodies," commented John Haurum, MD, D.Phil., Chief Scientific Officer of Symphogen.

"This new patent further strengthens our overall IP portfolio and reinforces our dominating position in this field."

"Our proprietary polyclonal antibody discovery and manufacturing technologies, Symplex™ and Sympress™, provide Symphogen with a fully-integrated platform to continually discover and develop new drugs that can fuel partnering opportunities and grow our proprietary pipeline."

Kirsten Drejer, Ph.D., Chief Executive Officer of Symphogen said, "Sym001, our candidate for the treatment of both Idiopathic Thrombocytopenic Purpura (ITP) and Hemolytic Disease of Newborns (HDN), is planned to enter clinical trials later this year and will be the first recombinant polyclonal antibody product to enter the clinic."

"Our Sympress™ platform has been applied successfully to manufacture batches for Sym001 and our partner, Biovitrum, has already scaled up the manufacturing under good manufacturing practice (GMP) conditions. We expect clinical trials will commence in the fourth quarter of this year."

Dr. Drejer is scheduled to provide an overview of Symphogen today at 3:30 p.m. Eastern Time at the Bear Stearns Annual Healthcare Conference being held at the Grand Hyatt in New York City.